Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia. (June 2019)

• Record Type: Journal Article
• Authors: Shioya, Sachiko; Masuda, Takeshi; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Nakashima, Taku; Miyamoto, Shintaro; Senoo, Tadashi; Iwamoto, Hiroshi; Ohshimo, Shinichiro; Fujitaka, Kazunori; Hamada, Hironobu; Hattori, Noboru
• Is Part Of: Respiratory medicine. Volume 152(2019)
• Page Start: 44
• Page End: 50
• Publication Date: 2019-06
• Subjects: Anti-aminoacyl-tRNA synthetase antibody -- Non-specific interstitial pneumonia -- Computed tomography -- Bronchoalveolar lavage fluid; anti-ARS anti-aminoacyl-tRNA synthetase -- BALF bronchoalveolar lavage fluid -- CRP C-reactive protein -- CT computed tomography -- CTD-ILD connective tissue disease-associated interstitial lung disease -- DLco diffusion capacity for carbon monoxide -- FVC forced vital capacity -- HRCT high-resolution computed tomography -- IIP idiopathic interstitial pneumonia -- IP interstitial pneumonia -- NSIP nonspecific interstitial pneumonia -- OP organizing pneumonia -- UIP usual interstitial pneumonia -- PSL prednisolone -- IS immunosuppressants; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2019.04.023
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: Background and purpose: Patients with anti-aminoacyl-tRNA synthetase (ARS) antibodies frequently experience complications of interstitial pneumonia (ARS-IP), and the computed tomography (CT) of ARS-IP frequently shows nonspecific interstitial pneumonia (NSIP) pattern. The CT pattern of ARS-IP might be different from that of idiopathic IP. However, the clinical differences in patients with ARS-IP and idiopathic IP showing the similar CT patterns have not yet been well studied. The objective of this study was to evaluate the clinical differences between patients with ARS-NSIP and idiopathic NSIP (I–NSIP). Methods: Two groups of 34 patients each, with ARS-NSIP and I–NSIP, who visited Hiroshima University Hospital between January 2005 and December 2017, were enrolled. Clinical features and outcomes were retrospectively compared between the two groups. Results: The ARS-NSIP group included more female patients and significantly younger patients than the I–NSIP group. The percentage of lymphocytes in bronchoalveolar lavage fluid (BALF) was significantly higher, and the CD4/CD8 ratio in BALF was significantly lower in the ARS-NSIP group compared with the I–NSIP group. The proportion of patients with traction bronchiectasis detected by CT was significantly higher in I–NSIP compared with ARS-NSIP. The number of patients who received corticosteroid and/or immunosuppressant therapy was significantly larger in the ARS-NSIP group than in the I–NSIP group. In addition, the patients in the I–NSIP group who underwent the immunosuppressive therapy demonstrated shorter survival than those who underwent no treatment; this tendency was not observed in the ARS-NSIP group. The 10-year survival rate of patients in the ARS-NSIP group was significantly higher than that of patients in the I–NSIP group (91.8% vs. 43.0%; log-rank, p = 0.012). The multivariate survival analysis revealed that positive anti-ARS antibody was an independent favorable prognostic factor in the patients with NSIP (OR, [95% CI]:0.12 [0.02–0.55], p = 0.013). Conclusions: Patients with ARS-NSIP had a significantly better prognosis than those with I–NSIP; this may be associated with the sensitivity to immunosuppressive therapies, and the different findings of BALF and HRCT between the two groups. Highlights: Clinical features and outcomes were retrospectively compared between the two groups of 34 patients each with ARS-NSIP and I–NSIP. Patients with ARS-NSIP had significantly better prognosis than those with I–NSIP, and positive anti-ARS antibody was an independent favorable prognostic factor. The differences in the BALF and HRCT findings between the two groups might be attributable to these results.